ITGAX and COVID-19: In the acute phase of COVID-19, many authors have reported a decrease in circulating blood dendritic cells, affecting both the total pool of these cells and their different subpopulations, including myeloid (CD11c+CD123lo/-) and plasmacytoid (CD11c-CD123+) dendritic cells [76,77,78].